Anadys Pharmaceuticals About
Anadys Pharmaceuticals: Anadys discovers, develops, and
commercializes novel small molecule medicines for the treatment of chronic viral
infections and bacterial infections. Anadys' primary therapeutic focus
encompasses the anti-infective market, including antivirals and antibacterials,
which represents over $40 billion in annual sales with a significant need for
novel and improved therapeutics. Pipeline
-- Clinical Trials:
Isatoribine
(ANA245) Hepatitis
C ANA
380 Hepatitis
B Isatoribine
(ANA245) Addition
Indications Oral
Prodrug ANA971 Additional
Indications Oral
Prodrug ANA975 Hepatitis
C
More on Anadys Pharmaceuticals: